08.22.08
Sancilio & Company, Inc. (SCI) opened its newly expanded 2,000-sq.-ft. contract manufacturing facility. The GMP facility specializes in small Batch manufacturing of tablets and capsules as well as packaging and labeling services.
The facility is adjacent to the company’s pharmaceutical laboratory, a climate-controlled facility for pharmaceutical, Biotechnology and Nutraceutical clients providing analytical services, which include formulation development, quality control, quality assurance and regulatory affairs.
According to Fred D. Sancilio, Ph.D., chief executive officer and chief scientist of SCI, “The new, fully cGMP compliant combined operation is FDA registered, and licensed for DEA Schedule 2, 3 and 4. The key attributes of both the manufacturing facility and the laboratory are rapid turnaround and competitive pricing.”
Nealie Newberger, Ph.D., vice president of laboratory services, said, “We anticipate that the addition of small batch contract manufacturing to our roster of services strategically positions the company as a full-service pharmaceutical and nutritional enterprise.”
The facility is adjacent to the company’s pharmaceutical laboratory, a climate-controlled facility for pharmaceutical, Biotechnology and Nutraceutical clients providing analytical services, which include formulation development, quality control, quality assurance and regulatory affairs.
According to Fred D. Sancilio, Ph.D., chief executive officer and chief scientist of SCI, “The new, fully cGMP compliant combined operation is FDA registered, and licensed for DEA Schedule 2, 3 and 4. The key attributes of both the manufacturing facility and the laboratory are rapid turnaround and competitive pricing.”
Nealie Newberger, Ph.D., vice president of laboratory services, said, “We anticipate that the addition of small batch contract manufacturing to our roster of services strategically positions the company as a full-service pharmaceutical and nutritional enterprise.”
